Charles River Laboratories International, Inc. — FY2020 Form 10-K
Reporting period: Fiscal year ended December 26, 2020. The filing also reports fourth-quarter results. Charles River is an early-stage contract research organization serving drug discovery, non-clinical development, research-model, and manufacturing-support markets.
Financial performance
| Metric | FY2020 | FY2019 | Change |
|---|---|---|---|
| Revenue | $2.924 billion | $2.621 billion | Up 11.5% |
| Operating income | $432.7 million | $351.2 million | Up 23.2% |
| Operating margin | 14.8% | 13.4% | Up 1.4 percentage points |
| Net income attributable to common shareholders | $364.3 million | $252.0 million | Up $112.3 million |
| Diluted EPS | $7.20 | $5.07 | Up 42.0% |
| Cash from operating activities | $546.6 million | $480.9 million | Up $65.6 million |
| Capital expenditures | $166.6 million | $140.5 million | Up $26.0 million |
Service revenue rose 13.1% to $2.296 billion; product revenue rose 6.1% to $627.8 million. Operating cash flow less capital expenditures was approximately $380.0 million. Cash and cash equivalents were $228.4 million at year-end, compared with $238.0 million a year earlier. Total debt and finance leases were $1.994 billion, including $50.2 million current; the company reported $1.2 billion available on its revolving credit facility.
Fourth-quarter results
FY2020 fourth-quarter revenue was $791.0 million, versus $691.1 million in FY2019 Q4. Operating income was $128.9 million versus $108.8 million; net income attributable to common shareholders was $143.2 million versus $80.3 million. Diluted EPS was $2.81 versus $1.61.
Segments and material changes
- Discovery and Safety Assessment (DSA): Revenue increased 13.5% to $1.837 billion; operating income increased 25.9% to $326.0 million. Growth reflected demand from biotechnology clients, pricing, and the Citoxlab acquisition; management said the segment was not significantly affected by COVID-19.
- Manufacturing Support: Revenue increased 10.8% to $515.4 million; operating income increased 24.8% to $181.5 million. Higher biologics testing and demand for endotoxin and avian products supported results, alongside improved production efficiencies.
- Research Models and Services (RMS): Revenue increased 6.3% to $571.2 million, including HemaCare and Cellero contributions. Operating income fell 23.3% to $102.7 million and margin declined to 18.0% from 24.9%, mainly due to COVID-related weakness in research-model product demand and acquisition-related amortization.
- Company-wide revenue growth also reflected foreign exchange. The company reported $100.9 million of net gains on venture-capital and strategic-equity investments, primarily from increases in publicly traded holdings and portfolio-company IPOs. These gains contributed to the increase in other income and net income and may be volatile.
Liquidity, outlook, risks, and unusual items
- Management stated that operating cash flows were expected to fund working capital, debt service, pension, and venture-capital obligations, and that it did not see significant going-concern uncertainty or material covenant-compliance risk based on current earnings expectations. No specific FY2021 revenue or earnings guidance is provided in the supplied filing text.
- The company borrowed an additional $150 million on its revolver early in 2020 as a precaution against market uncertainty, then repaid it during Q3. It reported compliance with credit-facility covenants at year-end. The facility matures in 2023; its interest rate is linked to LIBOR, whose phase-out creates transition risk.
- COVID-19 disrupted RMS research-model demand, particularly in Q2, followed by a recovery as clients resumed research in Q3 and Q4. DSA demand remained resilient; manufacturing effects included delayed instrument installations. Management reported supply-chain delays and higher costs and expected to increase inventory and supplies in 2021.
- The U.S. Pension Plan was terminated and settled in 2020, resulting in a non-cash settlement charge of $10.3 million. No goodwill or long-lived-asset impairment was identified for FY2020.
- Acquisitions included HemaCare for $379.8 million and Cellero for $37.4 million. After year-end, the company acquired Distributed Bio for approximately $83 million, with up to $21 million in contingent payments. It also announced a planned $875 million cash acquisition of Cognate BioServices, expected to be financed with available cash and revolver borrowings.
- Principal risks include the uncertain duration and effects of COVID-19; client cancellations or delays and contract cost overruns; limited supply of certain research models; competition and changes in outsourcing demand; cybersecurity and data-protection exposure (including a disclosed 2019 intrusion); foreign-exchange and interest-rate risk; acquisition integration; and regulatory, animal-welfare, and litigation-related exposures. The filing says no legal proceeding is material to the business or financial condition.
Most important facts for investors to verify
- Whether DSA and Manufacturing growth and margins can continue, and whether RMS demand and profitability recover from pandemic-related declines.
- How much FY2020 earnings depended on the $100.9 million investment gain, and the effect of investment valuations on future results.
- Debt, interest expense, available revolver capacity, covenant headroom, and the LIBOR transition; also the financing and integration impact of the announced Cognate acquisition.
- Whether working-capital movements, inventory buildup, and higher capital spending affect future cash generation.
- How quickly acquired businesses deliver expected growth and whether customer-relationship valuations and amortization assumptions remain supportable.